Transaction Overview - Kimberly-Clark is acquiring Kenvue to create a global health & wellness leader[20, 96] - Kenvue shareholders are expected to receive $3.50 in cash and 0.14625 K-C shares for each Kenvue share, representing total consideration of $21.01 per share[91] - Post-transaction, current K-C shareholders are expected to own approximately 54%, while current Kenvue shareholders are expected to own approximately 46%[91] - The transaction is expected to close in the second half of 2026[91] Strategic Rationale - The combination aims to drive growth, innovation, and market strength[23] - The combined company will have sales of $32 billion and EBITDA of $7 billion pre-synergies[30, 76, 77] - The combined company will have 10 iconic brands with over $1 billion in sales each[75] - Kimberly-Clark can scale Kenvue in China, Mexico, S Korea and Indonesia[90] - Kenvue can scale Kimberly-Clark categories in India and Western Europe[90] Synergy Opportunities - The transaction is expected to generate approximately $2.1 billion in total synergies[85] - Cost synergies are estimated at $1.9 billion, driven by optimization in COGS, sales, marketing, trade spend, and G&A[85, 87] - Margin flow through from revenue synergies is estimated at $0.2 billion[85] - The estimated cash cost to achieve synergies is $2.5 billion[88]

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year. The deal must still be approved by the shareholders of both companies. The combined company will have a huge stable of household brands under one roof, putting Kenvue’s Listerine mouthwa ...

Kimberly-Clark agreed to buy Kenvue in a cash and stock deal that gives the consumer-health company that owns brands like Tylenol for about $40 billion https://t.co/tT4IhxEEMh ...

Mergers and Acquisitions - Kimberly-Clark 同意以 487 亿美元（包括债务）收购 Kenvue [1] - 这次收购将 Huggies 制造商与 Tylenol 和其他消费者保健产品的所有者结合 [1]

From @WSJopinion: Ken Paxton is making a career of attacking business, and his suit against Kenvue, the maker of Tylenol, and its former parent, Johnson & Johnson, fits the pattern https://t.co/8SLEaoRKm4 ...

Core Viewpoint - U.S. Health Secretary Robert F. Kennedy Jr. stated that there is insufficient evidence to confirm that Kenvue's pain medicine Tylenol causes autism, but it should still be used with caution and under a physician's guidance [1] Summary by Relevant Categories Company - Kenvue's pain medicine Tylenol is under scrutiny regarding its potential link to autism [1] Industry - The statement from the U.S. Health Secretary highlights the ongoing debate and concerns within the pharmaceutical industry regarding the safety of over-the-counter medications like Tylenol [1]

Kenvue hired an executive from Procter & Gamble Co. to help the company get back on track after its biggest product, Tylenol, has come under scrutiny. https://t.co/QCJAMbxRS5 ...

Texas sued Tylenol maker Kenvue, alleging it deceived pregnant women about risks associated with autism https://t.co/YGZJ3rFHeD ...

Texas sued Johnson & Johnson and Kenvue, alleging the companies hid autism risks if mothers take Tylenol during pregnancy. The suit comes weeks after Trump claimed the drug caused autism in children, a link that has not been proven. https://t.co/iaX7luoKRv ...

Kenvue urged US regulators to deny a request warning against Tylenol’s use during pregnancy, laying out the most detailed defense of its biggest product after Trump administration officials tied its use to autism https://t.co/d9L4J0Wd3S ...